Artal Group S.A. Ambrx Biopharma Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.46 - $12.54 $2.12 Million - $18.2 Million	-1,450,000 Reduced 67.37%	702,291 $6.26 Million
Q4 2021 Feb 11, 2022	BUY	$8.11 - $13.91 $10.6 Million - $18.1 Million	1,302,291 Added 153.21%	2,152,291 $19.4 Million
Q2 2021 Aug 13, 2021	BUY	$15.95 - $19.6 $13.6 Million - $16.7 Million	850,000 New	850,000 $16.7 Million

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.